The Expert View: EasyJet, GKN and GlaxoSmithKline
A roundup of some of the best analyst commentary on shares, including Henderson Group and Portmeirion.
Investec downgrades EasyJet to 'hold'
Having been his key airlines pick last year, Investec analyst James Hollins says EasyJet (EZJ.L) shares have got ahead of themselves, and he's downgraded the group from 'buy' to 'hold'.
The shares have doubled in value over the past year, and although this was merited investors shouldn't get greedy, Hollins said.
'The stock was our key 2012 airlines pick, but the shares have outpaced the market and we now project a period of share price stability rather than material growth, coupled with uncertainty over the outcome of a major new aircraft order in 2013,' he said.
The possibility of bad weather stoppages and strike action - both notably absent last year - could also hit earnings this year, he added.
Shares in the company closed at 853p on Monday, down 18.3p or 2.1%.
Charles Stanley upgrades GKN on US car sales growth
Charles Stanley analyst Jeremy Batstone-Carr has upgraded engineering business GKN (GKN.L) from 'hold' to 'accumulate' based on US strong car sales and what he called an 'undemanding' valuation.
US automotive sales are forecast to grow 4.9% in 2013, Batstone-Carr noted, compared with a 1.7% decline in Europe. Although GKN has twice the exposure to Europe as the US, this should work out as a net positive, the analyst said.
'On balance of the facts, cautiously upbeat comments from GKN’s key customers, an undemanding price to earnings multiple and an expected improvement in trading profit margin we move our recommendation from Hold to Accumulate on weakness.'
Under Charles Stanley's methodology 'accumulate' means investors can expect an absolute total return of 5-15% over a year, compared with -5% to 5% under the 'hold' recommendation.
Shares in the company closed at 247p on Monday, up 3.8p or 1.6%.
Berenberg Bank sticks with GlaxoSmithKline despite gloomy 2012 projections
Drugsmaker GlaxoSmithKline (GSK.L) remains a 'buy', Berenberg Bank analyst Alistair Campbell says, despite taking a battering last year.
The company releases its full-year results on Wednesday 6 February, and Campbell is projecting a decline in earnings of around 3%. 'The company needs new products to resurrect growth, but pipeline contribution in 2013 will be thin,' he cautioned. 'The major opportunities from the pipeline should accelerate sales in 2014 and beyond, but will not help much this year.'
Nonetheless, he's still backing the shares on their long-term potential, with clinical data for cancer drug Mage-A3 and heart-attack treatment darapladib representing two 'wild card' opportunities ahead of an expected upturn in 2014.
Shares in the company closed at £14 on Monday, up 24p or 1.7%.
Shore Capital upgrades Henderson after PFI fund claim dropped
Investment management company Henderson Group (HGG.L)'s settlement of a claim against one of its private finance initiative (PFI) funds has spurred Shore Capital analyst Owen Jones to upgrade the shares from 'hold' to 'buy'.
Henderson announced on Friday that the claim against the fund is to be withdrawn, with it paying legal costs for the claimants, but without any admission of liability.
Jones believes investors are now presented with an attractive entry window: 'We upgrade our recommendation this morning noting the attractive positioning of the group’s funds and asset bed – mainly UK and Europe – but also on valuation grounds.
'In terms of metrics, Henderson trades on 12.7x to financial year 2012 going to 13.7x next year. These metrics compare to a sector average of 15.1x and 14.4x for the same periods.'
Shares in the company closed at 158.7p on Monday, up 7.5p or 5%.
Impressive dividend history makes Portmeirion a 'buy', Seymour Pierce says
Crockery maker Portmeirion (PMP.L)'s impressive dividend history makes it a 'buy', according to Seymour Pierce analyst Freddie George.
The company's latest results indicate that full-year profits will be in line with market expectations despite 'Superstorm Sandy' blowing US sales off course. Overall, the company expects sales to be about 3% above last year’s revenues at over £55 million and in line with George's forecasts.
'The stock, which continues to trade at a discount to peers, is valued at 11.9x FY12E earnings with a prospective dividend yield of almost 4%, more than 2x covered,' George said. 'The company has never cut its dividend in its 20 year-plus history of being a quoted company and over the last five years has grown the dividend by an average of 7% per annum.'
Seymour Pierce is a market maker for Portmeirion.
Shares in the company closed at 550p on Monday, up 2.5p or 0.5%.